about
Identification and functional characterization of a second chain of the interleukin-10 receptor complex.Stimulatory and inhibitory effects of interleukin (IL)-4 and IL-13 on the production of cytokines by human peripheral blood mononuclear cells: priming for IL-12 and tumor necrosis factor alpha productionDisrupted regulatory T cell homeostasis in inflammatory bowel diseasesActivation/modulation of adaptive immunity emerges simultaneously after 17DD yellow fever first-time vaccination: is this the key to prevent severe adverse reactions following immunization?Genomic expression profiling across the pediatric systemic inflammatory response syndrome, sepsis, and septic shock spectrum.Elevated expression of interleukins in lung adenocarcinomas induced by N-Nitrosobis(2-hydroxypropyl)amine in rats.Interleukin-10 suppression of myeloid cell activation--a continuing puzzle.Assessment by flow cytometry of cytokine production in malnourished children.Effects of TH1 and TH2 cytokines on CD8+ cell response against human immunodeficiency virus: implications for long-term survival.Outer membrane protein P6 of nontypeable Haemophilus influenzae is a potent and selective inducer of human macrophage proinflammatory cytokines.Leishmania interferes with host cell signaling to devise a survival strategy.Interleukin-10 increases Th1 cytokine production and cytotoxic potential in human papillomavirus-specific CD8(+) cytotoxic T lymphocytes.Modulation of T-cell responses to a recall antigen in human T-cell leukemia virus type 1-infected individualsRegulation of human CD4(+) alphabeta T-cell-receptor-positive (TCR(+)) and gammadelta TCR(+) T-cell responses to Mycobacterium tuberculosis by interleukin-10 and transforming growth factor beta.Complex role for the immune system in initiation and progression of pancreatic cancer.Current status of interleukin-10 and regulatory T-cells in cancerHypertonic stress regulates T cell function via pannexin-1 hemichannels and P2X receptorsPolymorphisms of interleukin-10 promoter are not associated with prognosis of advanced gastric cancer.Nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) oncoprotein induces the T regulatory cell phenotype by activating STAT3Men with low vitamin A stores respond adequately to primary yellow fever and secondary tetanus toxoid vaccination.Molecular Mechanism and Potential Targets for Blocking HPV-Induced Lesion DevelopmentHuman interleukin-10 expression in T/natural killer-cell lymphomas: association with anaplastic large cell lymphomas and nasal natural killer-cell lymphomas.Multiple CD4+ T cell subsets produce immunomodulatory IL-10 during respiratory syncytial virus infectionIL-13Ralpha2 and IL-10 coordinately suppress airway inflammation, airway-hyperreactivity, and fibrosis in miceEnforced IL-10 expression confers type 1 regulatory T cell (Tr1) phenotype and function to human CD4(+) T cells.Antigen-presenting cell production of IL-10 inhibits T-helper 1 and 17 cell responses and suppresses colitis in mice.Interleukin-10 production by myeloid-derived suppressor cells contributes to bacterial persistence during Staphylococcus aureus orthopedic biofilm infection.Establishment of memory for IL-10 expression in developing T helper 2 cells requires repetitive IL-4 costimulation and does not impair proliferation.Models of T cell anergy: is there a common molecular mechanism?Transfer of small resting B cells into immunodeficient hosts results in the selection of a self-renewing activated B cell population.Induction of anti-tumour lymphocytes in cancer patients after brief exposure to supernatants from cultures of anti-CD3-stimulated allogeneic lymphocytesExpanding roles for CD4 T cells and their subpopulations in tumor immunity and therapy.HIV-induced IL-6/IL-10 dysregulation of CD4 cells is associated with defective B cell help and autoantibody formation against CD4 cells.The combination of arsenic, interferon-alpha, and zidovudine restores an "immunocompetent-like" cytokine expression profile in patients with adult T-cell leukemia lymphoma.Immune suppression in tumors as a surmountable obstacle to clinical efficacy of cancer vaccinesInterleukin-10 promotes activation-induced cell death of SLE lymphocytes mediated by Fas ligand.Risk factors and outcome of bacterial infections in cirrhosisTargeting Cytokines in GVHD Therapy.The combination of IκB kinase β inhibitor and everolimus modulates expression of interleukin-10 in human T-cell lymphotropic virus type-1-infected T cells.CD3 hyporesponsiveness and in vitro apoptosis are features of T cells from both malignant and nonmalignant secondary lymphoid organs.
P2860
Q24315000-E30BEE44-9FD1-48EA-8713-0D9AB154DAFBQ24679477-6D83C72F-7321-44D4-8D7E-5EB8F960294DQ26774590-31CBB172-8408-4FFD-87BB-269D56AA5B19Q27478400-7E7B1FA6-04B1-40E1-8BFF-8E926FAD42A5Q30436233-9C51111B-BC05-4566-814E-AB036C4F09ACQ30950997-4886C77C-CABD-42F5-B763-648985DCAB44Q33340529-50FC9F0B-F769-4902-9C09-42D3E0D42BFAQ33736291-D30AE748-5799-474B-A1AC-F54EF7133036Q33759097-753C00B1-0788-4A6D-9636-9221E411F83EQ33768967-19ECCF78-F779-4666-913D-99C1F24D2352Q33781265-FEC325D3-E85E-4AC8-A1A3-251192E30E74Q33804742-55249DE5-43A3-4A88-B020-43FF3B9565C6Q33997886-A292AB4B-93B6-4653-B4B6-C5CB5983938CQ34002752-3F0C0601-C984-4AAC-951B-9636B532BCF6Q34093784-B0E18AC9-52A9-403F-A5D6-DCA9626946D0Q34374026-8F8E0278-FBAA-4DEA-A836-2CB61EB7EA2FQ34378750-274DF9C3-EEA4-4208-82D2-84F516D73314Q34744947-C4940B36-C601-4526-B38D-1A03D9D022EEQ34773094-7ED16C39-695E-42F3-99E0-B46815AC6549Q35151361-5C21039D-6FB3-4545-98A2-AB0F7B3B701EQ35636308-492CC6CB-7EA0-4EE4-A50A-5E40EF7B9B55Q35753497-84BBCF12-B94E-4987-83A6-E32220A56793Q35831296-ABC351E0-8AF3-4DF9-B250-F436899918FBQ35995705-A595816B-F003-4B2F-9F6E-D9052F5AC0B4Q36220670-0E0DDF8D-FA30-4D9D-BCB8-6FBD049A8E0CQ36294669-48863B54-90AE-41C1-B913-C71943AECE29Q36322346-959C8C52-CB49-4A47-9530-AA13F4393836Q36349742-B087C59A-63FC-4914-BE5E-B6FFABF307F0Q36366967-760B7313-AC83-454C-89C3-86B1CD8A9FAEQ36367974-59A72C4A-543E-48B0-BD64-34BBC5C1838BQ36431237-316BDAA5-72FE-47E0-A1BD-DEA5227B1D9BQ36715205-C83B32FF-6F1E-4855-BEAC-844A67D1A3A8Q36895399-20676DED-1F21-4ADA-80C7-6DC8CF21F697Q37116770-51E4CB52-2174-4513-95F7-79F115E85155Q37137360-3FE948E0-550E-4542-9378-22A9AD85E09CQ37375157-9BDA63AC-680E-4FE2-8FEB-C101BA98AB29Q37629681-D3E02470-9279-4E59-85F5-3DE4905BAF9BQ38640486-1A806C60-3835-4D99-911E-A8DE283B0D05Q39218366-12612A39-918E-4DB4-9828-91AC81EB0745Q39813239-E80AF299-CFFC-4D20-A7C4-9DADC1C83473
P2860
description
1993 nî lūn-bûn
@nan
1993 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1993 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
name
Human interleukin-10 can directly inhibit T-cell growth
@ast
Human interleukin-10 can directly inhibit T-cell growth
@en
Human interleukin-10 can directly inhibit T-cell growth
@en-gb
Human interleukin-10 can directly inhibit T-cell growth
@nl
type
label
Human interleukin-10 can directly inhibit T-cell growth
@ast
Human interleukin-10 can directly inhibit T-cell growth
@en
Human interleukin-10 can directly inhibit T-cell growth
@en-gb
Human interleukin-10 can directly inhibit T-cell growth
@nl
prefLabel
Human interleukin-10 can directly inhibit T-cell growth
@ast
Human interleukin-10 can directly inhibit T-cell growth
@en
Human interleukin-10 can directly inhibit T-cell growth
@en-gb
Human interleukin-10 can directly inhibit T-cell growth
@nl
P2093
P921
P1433
P1476
Human interleukin-10 can directly inhibit T-cell growth
@en
P2093
P304
P407
P577
1993-06-01T00:00:00Z